OR WAIT 15 SECS
Clarithromycin oral suspension approved for Ranbaxy Pharmaceuticals
Clarithromycin for Oral Suspension, USP, has been approved by the FDA for Ranbaxy Pharmaceuticals in strengths of 125 mg/5 ml and 250 mg/5 ml. The agent is bioequivalent to Biaxin Granules in the same strengths from Abbott Laboratories. Clarithromycin is indicated for the treatment of mild to moderate infections causes by susceptible microorganisms.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.